Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Accelerating global innovation to address antibacterial resistance: introducing CARB-X.

Literature DB >> 27469032

Accelerating global innovation to address antibacterial resistance: introducing CARB-X.

Kevin Outterson^1,2, John H Rex^3,4, Tim Jinks⁵, Peter Jackson⁶, John Hallinan⁷, Steve Karp⁸, Deborah T Hung^9,10,11, Francois Franceschi¹², Tyler Merkeley¹³, Christopher Houchens¹³, Dennis M Dixon¹², Michael G Kurilla¹², Rosemarie Aurigemma¹², Joseph Larsen¹³.

Abstract

A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public-private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.

Entities: Gene

Mesh：

Substances：
Anti-Bacterial Agents

Year: 2016 PMID： 27469032 DOI： 10.1038/nrd.2016.155

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

2 in total

1. Antibiotic resistance-the need for global solutions.

Authors: Ramanan Laxminarayan; Adriano Duse; Chand Wattal; Anita K M Zaidi; Heiman F L Wertheim; Nithima Sumpradit; Erika Vlieghe; Gabriel Levy Hara; Ian M Gould; Herman Goossens; Christina Greko; Anthony D So; Maryam Bigdeli; Göran Tomson; Will Woodhouse; Eva Ombaka; Arturo Quizhpe Peralta; Farah Naz Qamar; Fatima Mir; Sam Kariuki; Zulfiqar A Bhutta; Anthony Coates; Richard Bergstrom; Gerard D Wright; Eric D Brown; Otto Cars
Journal: Lancet Infect Dis Date: 2013-11-17 Impact factor: 25.071

Review 2. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.

Authors: John H Rex; Kevin Outterson
Journal: Lancet Infect Dis Date: 2016-04 Impact factor: 25.071

2 in total

13 in total

1. Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo.

Authors: Erin K Sully; Bruce L Geller; Lixin Li; Christina M Moody; Stacey M Bailey; Amy L Moore; Michael Wong; Patrice Nordmann; Seth M Daly; Carolyn R Sturge; David E Greenberg
Journal: J Antimicrob Chemother Date: 2017-03-01 Impact factor: 5.790

Review 2. Structural approaches to pathway-specific antimicrobial agents.

Authors: Michael E Johnson; Leslie W-M Fung
Journal: Transl Res Date: 2020-02-06 Impact factor: 7.012

3. Preclinical antibiotic pipeline gets a pick-me-up.

Authors: Asher Mullard
Journal: Nat Rev Drug Discov Date: 2017-10-30 Impact factor: 84.694

Review 4. Using bacterial genomes and essential genes for the development of new antibiotics.

Authors: Francisco R Fields; Shaun W Lee; Michael J McConnell
Journal: Biochem Pharmacol Date: 2016-12-08 Impact factor: 5.858

Review 5. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.

Authors: Victoria L Simpkin; Matthew J Renwick; Ruth Kelly; Elias Mossialos
Journal: J Antibiot (Tokyo) Date: 2017-11-01 Impact factor: 2.649

Review 6. Kunkel Lecture: Fundamental immunodeficiency and its correction.

Authors: Carl Nathan
Journal: J Exp Med Date: 2017-07-12 Impact factor: 14.307

Review 7. Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development.

Authors: Ursula Theuretzbacher; Christine Årdal; Stephan Harbarth
Journal: Infect Dis Rep Date: 2017-03-30